A Gene Variant Could Cut GLP-1 Drugs’ Blood-Sugar Benefit Nearly In Half

Could Your Genes Decide Whether Ozempic-Type Drugs Work for You?

Drugs like semaglutide, sold as Ozempic and Wegovy, have become some of the most talked-about medications on the planet, prescribed to millions for type 2 diabetes and weight loss alike. A large international study now suggests that for a subset of people carrying specific gene variants, GLP-1 drugs may lose nearly half their power to control blood sugar. The study looked at blood sugar control specifically, not weight loss, raising a pointed question: could a genetic test help doctors pick the right diabetes treatment from the start?

Published in Genome Medicine, the research focuses on a gene called PAM, which provides the blueprint for the only enzyme responsible for a finishing step in producing dozens of hormones, including GLP-1, the gut hormone GLP-1 drugs are designed to imitate. Two variants in this gene, already known to raise diabetes risk, appear to gum up that enzyme’s machinery. Consequences ripple outward: altered hormone levels, disrupted gut signaling, and a weaker response to GLP-1-based medications.

One statistic stands out. Among carriers of one PAM variant, only about 11.5% achieved the recommended blood sugar target after starting a GLP-1-based drug, compared with 25.3% of non-carriers, a gap representing real people with poorly controlled diabetes despite taking medications their doctors expected to work.

A Faulty Enzyme Leaves More GLP-1 in the Blood, But Less Effect

To understand what these gene variants do inside the body, researchers combined work with human volunteers, mouse models, lab-grown cells, and clinical databases across several countries.

Researchers recruited carriers of the two PAM risk variants, p.S539W and p.D563G, along with matched non-carriers from the Oxford Biobank in the United Kingdom. Blood samples measured how well the PAM enzyme was functioning. Carriers of p.S539W showed a 52% reduction in enzyme activity, while p.D563G carriers had a 20% reduction. The enzyme still worked, just not nearly as well.

Then came a paradox. Despite reduced enzyme capacity, carriers of both variants had higher circulating GLP-1 after meals, confirmed in Danish population studies. More GLP-1 sounds beneficial, since the hormone helps manage blood sugar after eating. But in p.S539W carriers, the body was almost 20% less responsive to its own GLP-1. More hormone circulating, doing less work, a mismatch researchers describe as GLP-1 resistance.

Mice engineered to lack the PAM enzyme entirely in adulthood mirrored this pattern: elevated GLP-1, blunted response to it. One telling experiment involved gastric emptying, the rate at which food leaves the stomach, which GLP-1 normally slows, one of the main ways GLP-1 drugs curb blood sugar spikes after meals. The engineered mice showed faster than normal gastric emptying, and a compound that activates the same receptor as GLP-1 drugs failed to slow their stomachs down. The mouse model used complete removal of the enzyme rather than the partial reduction seen in human carriers, which may exaggerate these effects.

The Gene Variant Cut Real-World GLP-1 Drug Response Nearly in Half

This laboratory work raised the question that matters most to patients: does it translate to real-world differences in how well diabetes drugs work?

Researchers pooled data from 1,119 participants across three clinical groups, all with type 2 diabetes and treated with GLP-1-based drugs. They compared how much each person’s long-term blood sugar marker, HbA1c, dropped after starting therapy, then checked whether the PAM variants made a difference. They did, substantially. Carriers of p.S539W saw their blood sugar marker drop by an average of 0.69 percentage points, versus 1.24 points for non-carriers, a statistically significant difference. In practical terms, that’s a 44% smaller blood-sugar-lowering response to GLP-1 therapy.

Researchers also checked three other diabetes medications: sulphonylureas, metformin, and DPP-4 inhibitors. No difference turned up, since impaired response was specific to GLP-1-based therapies, which makes sense given that PAM directly processes GLP-1 itself.

A Genetic Test Could Flag Poor GLP-1 Responders Early

For patients, the upshot is straightforward. A drug that’s supposed to bind to GLP-1 receptors and lower blood sugar runs into receptors that have effectively stopped listening, so a chunk of its power gets lost before it can do its job.

Right now, when someone is diagnosed with type 2 diabetes, doctors choose among medications based on guidelines, cost, side effects, and clinical judgment. If a drug doesn’t work well enough, patient and doctor find out months later when a blood test shows little improvement. A genetic test could, in theory, help identify patients with a reduced average response to GLP-1 drugs and inform therapy choice from the outset.

Study authors describe PAM genotype as a “novel pharmacogenomic determinant of GLP-1RA response” and call for incorporating it into precision medicine for diabetes care. With GLP-1 drugs prescribed to millions, knowing who is less likely to respond well could save time, money, and health.

Important caveats remain. This is a real average difference between two groups of people, not proof that a genetic test could tell any one patient exactly how they’ll respond. Clinical groups here weren’t originally designed to test this genetic hypothesis, and the PAM variants are uncommon enough that findings had to be pooled across studies to hold up. Much of the human research involved participants of European ancestry, so the findings need testing in more diverse populations, and larger, purpose-built trials before genetic testing becomes part of routine practice.

---

Disclaimer: This article is based on peer-reviewed research and is intended for general informational purposes. It is not medical advice. Anyone taking or considering a GLP-1 medication should talk with their doctor before making any changes to their treatment.

---